Bradycardia-induced heart failure with preserved ejection fraction successfully treated with empagliflozin and theophylline: a case report.

ABSTRACT:

Background

The SGLT2 inhibitor empagliflozin has recently gained approval for treating heart failure (HF) across the entire spectrum of ejection fractions including heart failure with preserved ejection fraction (HFpEF). Bradycardia-induced HF, previously described in the literature as bradycardiomyopathy, is an uncommon cause of HFpEF.

Case summary

Herein, we describe a case of a young, 32-year-old woman with no prior medical history who was referred to the hospital due to progressive fatigue and exercise intolerance. She exhibited junctional bradycardia and sinus node dysfunction on electrocardiographic examination, was hypotensive, and had significantly elevated NT-proBNP levels at admission. Transthoracic echocardiographic examination (TTE) revealed preserved systolic fu

SUBMITTER: Miric D 

PROVIDER: S-EPMC11404508 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature